DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged.
Acknowledgment is made of applicant's claim for foreign priority based on applications KR10-2016-0102825 and KR10-2016-0103209 filed on 08/12/2016; KR10-2016-0126856 filed on 09/30/2016; and KR10-2016-0146920 filed on 11/04/2016. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Information Disclosure Statement
The information disclosure statement filed 01/17/2025 and 07/07/2025 have been fully considered by examiner and made of record.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. U.S. Patent No. 10,045,325 in view of Woo et al (US 2013/0122930).
Instant Application 18/584,367
U.S. Patent No. 10,045,325
Claim 1
Claim 1
Regarding Claim 1, Patent ‘325 Claim 1 teach all aspects of the claimed invention except for determining, based on an NB PRS muting indicator, that first NB PRS subframes of a cell are not muted.
In the same field of endeavor, Woo teaches determining, based on an NB PRS muting indicator, that first NB PRS subframes of a cell are not muted ([0087], prs-MutingInfo field indicates a PRS muting configuration of a reference cell, a first bit of the PRS muting sequence may correspond to a first PRS occasion that starts after the SFN of the reference cell becomes 0, PRS muting sequence is valid for all subframes after the UE receives the PRS muting information field, if the PRS muting information field is not provided, the UE may assume that PRS muting is not applied to the reference cell).
It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Patent ‘325, to further include determining whether there is a muting indicator among the bitmap and configuration parameters obtained signaling the muting of the positioning reference signal, as taught in Woo, in order to ensure proper decoding of received reference signals and reduce ambiguity by providing a means for the terminal device to recognize muting patterns of reference signals. (See Woo [0008-0009]) As such, the instant application claims are an obvious variation of the patent claims and are therefore not patentably distinct therefrom.
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. U.S. Patent No. 10,420,060 in view of Woo et al (US 2013/0122930).
Instant Application 18/584,367
U.S. Patent No. 10,420,060
Claim 1
Claim 1
Regarding Claim 1, Patent ‘060 Claim 1 teach all aspects of the claimed invention except for determining, based on an NB PRS muting indicator, that first NB PRS subframes of a cell are not muted.
In the same field of endeavor, Woo teaches determining, based on an NB PRS muting indicator, that first NB PRS subframes of a cell are not muted ([0087], prs-MutingInfo field indicates a PRS muting configuration of a reference cell, a first bit of the PRS muting sequence may correspond to a first PRS occasion that starts after the SFN of the reference cell becomes 0, PRS muting sequence is valid for all subframes after the UE receives the PRS muting information field, if the PRS muting information field is not provided, the UE may assume that PRS muting is not applied to the reference cell).
It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Patent ‘060, to further include determining whether there is a muting indicator among the bitmap and configuration parameters obtained signaling the muting of the positioning reference signal, as taught in Woo, in order to ensure proper decoding of received reference signals and reduce ambiguity by providing a means for the terminal device to recognize muting patterns of reference signals. (See Woo [0008-0009]) As such, the instant application claims are an obvious variation of the patent claims and are therefore not patentably distinct therefrom.
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 10,652,852 in view of Woo et al (US 2013/0122930).
Instant Application 18/584,367
U.S. Patent No. 10,652,852
Claim 1
Claim 1
Regarding Claim 1, Patent ‘852 Claim 1 teach all aspects of the claimed invention except for determining, based on an NB PRS muting indicator, that first NB PRS subframes of a cell are not muted.
In the same field of endeavor, Woo teaches determining, based on an NB PRS muting indicator, that first NB PRS subframes of a cell are not muted ([0087], prs-MutingInfo field indicates a PRS muting configuration of a reference cell, a first bit of the PRS muting sequence may correspond to a first PRS occasion that starts after the SFN of the reference cell becomes 0, PRS muting sequence is valid for all subframes after the UE receives the PRS muting information field, if the PRS muting information field is not provided, the UE may assume that PRS muting is not applied to the reference cell).
It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Patent ‘852, to further include determining whether there is a muting indicator among the bitmap and configuration parameters obtained signaling the muting of the positioning reference signal, as taught in Woo, in order to ensure proper decoding of received reference signals and reduce ambiguity by providing a means for the terminal device to recognize muting patterns of reference signals. (See Woo [0008-0009]) As such, the instant application claims are an obvious variation of the patent claims and are therefore not patentably distinct therefrom.
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. U.S. Patent No. 10,873,923.
Instant Application 18/584,367
U.S. Patent No. 10,873,923
Claim 1
Claim 1
Although the conflicting claims are not identical, they are not patentably distinct from each other because the Patent claims include all the limitations of the instant application claims, respectively. Hence, the instant application claims are generic to the species of invention covered by the respective patent claims. As such, the instant application claims are anticipated by the patent claims and are therefore not patentably distinct therefrom (See Eli Lilly and Co. v. Barr Laboratories Inc., 58 USPQ2D 1869, " a later genus claim limitation is anticipated by, and therefore not patentably distinct from, an earlier species claim", In re Goodman, 29 USPQ2d 2010, "Thus, the generic invention is 'anticipated' by the species of the patented invention" and the instant “application claims are generic to species of invention covered by the patent claim, and since without terminal disclaimer, extant species claim preclude issuance of generic application claims”).
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. U.S. Patent No. 11,438,864.
Instant Application 18/584,367
U.S. Patent No. 11,438,864
Claim 1
Claim 1
Although the conflicting claims are not identical, they are not patentably distinct from each other because the Patent claims include all the limitations of the instant application claims, respectively. Hence, the instant application claims are generic to the species of invention covered by the respective patent claims. As such, the instant application claims are anticipated by the patent claims and are therefore not patentably distinct therefrom (See Eli Lilly and Co. v. Barr Laboratories Inc., 58 USPQ2D 1869, " a later genus claim limitation is anticipated by, and therefore not patentably distinct from, an earlier species claim", In re Goodman, 29 USPQ2d 2010, "Thus, the generic invention is 'anticipated' by the species of the patented invention" and the instant “application claims are generic to species of invention covered by the patent claim, and since without terminal disclaimer, extant species claim preclude issuance of generic application claims”).
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. U.S. Patent No. 11,968,643.
Instant Application 18/584,367
U.S. Patent No. 11,968,643
Claim 1
Claim 1
Although the conflicting claims are not identical, they are not patentably distinct from each other because the Patent claims include all the limitations of the instant application claims, respectively. Hence, the instant application claims are generic to the species of invention covered by the respective patent claims. As such, the instant application claims are anticipated by the patent claims and are therefore not patentably distinct therefrom (See Eli Lilly and Co. v. Barr Laboratories Inc., 58 USPQ2D 1869, " a later genus claim limitation is anticipated by, and therefore not patentably distinct from, an earlier species claim", In re Goodman, 29 USPQ2d 2010, "Thus, the generic invention is 'anticipated' by the species of the patented invention" and the instant “application claims are generic to species of invention covered by the patent claim, and since without terminal disclaimer, extant species claim preclude issuance of generic application claims”).
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. U.S. Patent No. 12,349,102.
Instant Application 18/584,367
U.S. Patent No. 12,349,102
Claim 1
Claim 1
Although the conflicting claims are not identical, they are not patentably distinct from each other because the Patent claims include all the limitations of the instant application claims, respectively. Hence, the instant application claims are generic to the species of invention covered by the respective patent claims. As such, the instant application claims are anticipated by the patent claims and are therefore not patentably distinct therefrom (See Eli Lilly and Co. v. Barr Laboratories Inc., 58 USPQ2D 1869, " a later genus claim limitation is anticipated by, and therefore not patentably distinct from, an earlier species claim", In re Goodman, 29 USPQ2d 2010, "Thus, the generic invention is 'anticipated' by the species of the patented invention" and the instant “application claims are generic to species of invention covered by the patent claim, and since without terminal disclaimer, extant species claim preclude issuance of generic application claims”).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARGARET G WEBB whose telephone number is (571)270-7803. The examiner can normally be reached M-F 9:00-6:00 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Appiah can be reached on (571) 272-7904. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MARGARET G WEBB/ Primary Examiner, Art Unit 2641